drugset / Trial / NCT02193828
Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules
RandomizedParallel-groupTriple-blindTreatment
Summary
The objectives of this study are to assess the safety and effectiveness of AA4500 in treating palmar Dupuytren's disease nodules.
Timeline
- Start
- 2014-07
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.25 mg | Other |
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.4 mg | Other |
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.6 mg | Other |